Myriad to Enter Proteomics Market with $80M Purchase of Rules-Based Medicine

With the deal, Myriad will acquire RBM's biomarker discovery platform as well as its pipeline of proprietary protein biomarker-based diagnostics, including two tests that a Myriad official said were "relatively close to commercial launch."

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.